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Background: Data examining the characteristics of patients with frequent exacerbations of chronic obstructive
pulmonary disease (COPD) and associated hospitalisations and mortality are scarce.
Methods: Post-hoc analysis of the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) trial,
targeting exacerbations as the primary endpoint. Patients were classified as non-, infrequent, and frequent
exacerbators (0, 1, or ≥ 2 exacerbations during study treatment), irrespective of study treatment. A multivariate
Cox regression model assessed the effect of covariates on time to first exacerbation.
Results: In total, 7376 patients were included in the analysis: 63.5% non-exacerbators, 22.9% infrequent, 13.6%
frequent exacerbators. Factors significantly associated with exacerbation risk were age, sex, body mass index,
COPD duration and severity, smoking history, baseline inhaled corticosteroid use, and preceding antibiotic or
systemic corticosteroid courses. Frequent exacerbators had greater severity and duration of COPD, received more
pulmonary medication, and ≥ 2 systemic corticosteroid or antibiotic courses in the preceding year, and were more
likely to be female and ex-smokers. The small proportion of frequent exacerbators (13.6%) accounted for 56.6% of
exacerbation-related hospitalisations, which, overall, were associated with a three-fold increase in mortality.
Conclusion: The frequent exacerbator phenotype was closely associated with exacerbation-related hospitalisations,
and exacerbation-related hospitalisations were associated with poorer survival.
Trial registration: NCT00563381; Study identifier: BI 205.389.
Keywords: Chronic obstructive pulmonary disease, Exacerbations, Mortality, Hospitalisation, Tiotropium,
Salmeterol, GOLDBackground
Exacerbations are an important element of the natural
course of chronic obstructive pulmonary disease (COPD)
and a key component of disease assessment, both in the
clinic and as an outcome measure in clinical trials [1-3].
Exacerbations impact disease progression, quality of life
and prognosis [4-6].
Therefore, the 2011 revision and 2013 update of the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) recommendations highlight the important influ-
ence of exacerbations on future risk in COPD, making* Correspondence: claus.vogelmeier@med.uni-marburg.de
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reproduction in any medium, provided the ortheir prevention a priority [3,7]. In a large observational
cohort study, a history of COPD exacerbations was the
most reliable predictor of future events, regardless of the
severity of airflow limitation [8]. However, COPD is a
heterogeneous disease [9,10], with considerable variability
in exacerbation susceptibility between patients. The
term ‘frequent exacerbator’ has been proposed to describe
a distinct and stable COPD phenotype at high risk of
recurrent events [8,11]. Although these studies were not
specifically designed to detect exacerbations of COPD,
identifying factors associated with COPD exacerbation risk
remains an important aspect of patient monitoring and
may help to guide the use of preventative interventions.
The 1-year Prevention Of Exacerbations with Tiotropium
in COPD (POET-COPD) study complements and extends
the few previous reports on exacerbation phenotypes. Thisd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the primary endpoint, enables us to study more than 4400
moderate or severe exacerbations [12]. The purpose of
this post-hoc analysis of the POET-COPD trial was to:
determine the factors contributing to exacerbation risk;
evaluate the characteristics of patients with infrequent,
frequent and severe exacerbations in a large patient
population; and, assess the effects of exacerbations on
the incidence of hospitalisations and mortality.
Methods
Study design
POET-COPD (ClinicalTrials.gov number: NCT00563381)
was a prospective, 1-year, randomised, double-blind,
double-dummy, parallel-group study comparing effects
of tiotropium (18 μg once daily via HandiHalerW) and
salmeterol (50 μg twice daily via pressurised metered-dose
inhaler) on moderate and severe COPD exacerbations.
The study, carried out in 725 centres in 25 predominantly
European countries from January 2008 until April 2010,
was conducted in accordance with the Declaration of
Helsinki (1996) and Good Clinical Practice. Ethical
approval was obtained from independent ethics com-
mittees or institutional review boards and all patients
provided written informed consent. Details of the
study protocol and main results have been described
previously [12,13].
Patients
Briefly, patients were eligible for study inclusion if they
were aged ≥ 40 years, had a smoking history of ≥ 10
pack-years, and a diagnosis of moderate to very severe
COPD with a post-bronchodilator forced expiratory vol-
ume in 1 second (FEV1) of ≤ 70% of the predicted value,
and FEV1/forced vital capacity ratio of ≤ 70% [12]. A
documented history of ≥ 1 exacerbation treated with
systemic glucocorticoid or antibiotic therapy, or hospi-
talisation within the previous year, was required. The
main exclusion criteria were a diagnosis of asthma,
severe cardiovascular disorders, moderate or severe renal
insufficiency (creatinine clearance ≤ 50 ml/min) and
significant diseases other than COPD that in the opinion
of the Investigator may put the patient at risk or may
influence either the results of the study or the patient’s
ability to participate in the trial. The use of systemic
corticosteroid medication at unstable doses or at doses
in excess of the equivalent of 10 mg prednisolone per
day or 20 mg every other day was also excluded. Full
details of exclusion criteria have been reported previously
[12,13]. Participation in a pulmonary rehabilitation
programme was not an exclusion criterion in the trial.
Throughout the study, patients were permitted to continue
previously prescribed COPD treatments (including stable
systemic corticosteroids up to 10 mg prednisolone orequivalent daily); only anticholinergics and β2-agonists
other than salbutamol for rescue medication were
prohibited.
Assessments
The primary endpoint of POET-COPD was time to first
COPD exacerbation. Secondary exacerbation endpoints
included a variety of time-to-event and number-of-event
outcomes. An exacerbation was defined as an increase
in, or new onset of, ≥ 2 respiratory symptoms (cough,
sputum, dyspnoea, wheezing, chest tightness) with ≥ 1
symptom lasting ≥ 3 days and leading the patient’s
attending physician to initiate treatment with systemic
corticosteroids and/or antibiotics (moderate exacerbation)
or hospitalisation (severe exacerbation).
Data on the occurrence of exacerbations and their
treatment were collected prospectively for all patients
while on study treatment via case report forms that were
administered during scheduled clinic visits (at Months 2,
4, 8 and 12), and by monthly telephone contact between
these visits. The end of an exacerbation was determined
by the investigator; a recurrent exacerbation was defined
as an event that occurred ≥ 7 days after the preceding
exacerbation.
Statistical analysis
All randomised patients who received at least one dose
of study medication were classified, irrespective of study
drug allocation, according to their exacerbation frequency
into ‘non-exacerbators’, ‘infrequent exacerbators’ and
‘frequent exacerbators’ if they had experienced 0, 1 or ≥ 2
exacerbations, respectively, while on study treatment.
Descriptive statistical methods, including exposure-
adjusted crude incidence rates, were applied to characterise
non-, infrequent, or frequent exacerbators as well as those
patients who experienced ≥ 1 severe exacerbation.
A multivariate Cox regression model was developed
for time to first COPD exacerbation, using the stepwise
selection procedure to assess the association between
baseline covariates and exacerbation risk. This selection
procedure consisted of a series of alternating forward
selection and backward elimination steps [14].
A covariate had to be significant at the 0.25 level before
being entered into the model and significant at the 0.15
level to remain in the model. Study treatment was an
additional covariate in the multivariate model to account
for its known effect on time to first exacerbation. Overall
p-values were calculated using Wald’s χ2 test for optimal
model.
Sensitivity analyses of the multivariate Cox regression
model selection were performed using both backward
selection and completer analysis. Robustness of the model
selection was checked via the bootstrapping technique
based on 1000 repetitions of the selection procedure.
Figure 1 Multivariate model for time to first COPD exacerbation (all) and effect of covariates. Time to first COPD exacerbation was
analysed using multivariate Cox regression with stepwise model selection. Potential covariates originally also included ‘smoking status’ with
categories ‘non-current smoker’; ‘current smoker’ and ‘concomitant diagnoses at baseline’ with categories ‘0, 1 and > 1’ but turned out to be
non-significant for the significance level chosen. a≥ 1 exacerbation versus no exacerbation. bOverall p-value based on Wald’s χ2 test for optimal
model. cIncludes 23 GOLD category 1 patients. BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary disease;
GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroids.
Figure 2 Exacerbation frequency and severity of airflow
limitation (GOLD category). GOLD category 2 includes 23 patients
with GOLD category 1. GOLD = Global Initiative for Chronic
Obstructive Lung Disease.
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Cox regression were performed on data from the sub-
group of patients who completed planned study treat-
ment. All statistical analyses were performed using SASW
software, version 9.2 (SAS Institute Inc, Cary, NC, USA).
Results
Patients
In total, 7376 patients received at least one dose of study
medication. There were 4411 COPD exacerbation episodes
among 2691 (36.5%) patients, and 725 severe exacerbations
among 598 (8.1%) patients. Of all exacerbations, 23%
(1004/4411) were followed by ≥ 1 recurrent exacerbation
and 39% of all exacerbations (1720/4411) were recurrent
exacerbations.
Covariates associated with exacerbation risk
The Forest plot in Figure 1 shows the results of the step-
wise model selection for time to first COPD exacerbation
(moderate or severe) using multivariate Cox regression.
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exacerbation risk were age, sex, COPD severity (by GOLD
category), body mass index (BMI), inhaled corticosteroid
(ICS) use at baseline, COPD duration, smoking history
(pack-years) and the extent of antibiotic or oral cortico-
steroid use due to breathing problems in the previous
year. The covariates ‘smoking status’ and ‘concomitant
diagnoses at baseline’ were non-significant (p > 0.4).
Robustness of the model selection was confirmed by the
bootstrapping technique. The risk of a first exacerbation
was higher for women compared with men (hazard ratio
[HR], 1.31; 95% confidence interval [CI], 1.19 to 1.43); for
patients with a mean baseline BMI < 20 kg/m2 compared
with BMI ≥ 25 to < 30 kg/m2 (HR, 1.29; 95% CI, 1.11 to
1.50) or ≥ 30 kg/m2 (HR, 1.34; 95% CI, 1.15 to 1.57);Figure 3 Frequency distribution of patients with exacerbations by nupatients with ICS use at baseline versus no ICS use
(HR, 1.36; 95% CI, 1.26 to 1.48); patients on ≥ 2 antibiotic
courses versus < 2 antibiotic courses (HR, 1.33; 95% CI,
1.21 to 1.46); and patients on ≥ 2 systemic corticosteroid
courses versus < 2 corticosteroid courses due to breathing
problems in the preceding year (HR, 1.37; 95% CI, 1.22 to
1.54), respectively. Sensitivity analyses confirmed these
findings (Additional file 1: Table S1).
Though patients with moderate airflow limitation (GOLD
category 2) were associated with a lower exacerbation
risk than those at GOLD category 3/4, 11.6% (416/
3591) of patients in GOLD category 2 still experienced ≥ 2
exacerbations during the study period compared with
15.6% (588/3762) of patients with severe or very severe
airflow limitation (GOLD category 3 and 4) (Figure 2).mber of (A) exacerbations and (B) severe exacerbations.
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The frequency of exacerbations and exacerbation-related
hospitalisations is shown in Figure 3A and 3B. The
distributions are highly skewed, with most patients
experiencing ≤ 1 moderate or severe exacerbation and
only a minority of patients exhibiting a higher frequency
of events during study treatment. Based on these data,
4685 (63.5%) patients were categorised as non-exacerba-
tors, 1687 (22.9%) as infrequent and 1004 (13.6%) as fre-
quent exacerbators; 598 patients (8.1%) were categorised
as severe exacerbators. The demographics and baseline
characteristics for these patient categories are shown in
Table 1.
Significant differences in baseline characteristics between
patient subgroups were observed for all characteristics
except for age and pack-years of smoking. Frequent
exacerbators were more likely than non- or infrequent
exacerbators to have a longer duration of COPD (p <
0.0001), more severe airflow limitation as assessed by FEV1
measures or GOLD category (p < 0.0001), and to have
received pulmonary medication at baseline (p < 0.0001 for
each drug class; p = 0.0094 for oxygen) or ≥ 2 courses ofTable 1 Demographics and baseline characteristics
Non-exacerbators Inf
(n = 4685)
Male sex, % 76.4
Age, yearsa 62.8 (9.0)
BMI, kg/m2a 26.8 (5.0)
COPD duration, yearsa 7.6 (6.7)
Current smokers, % 48.8
Smoking history, pack-yearsa 38.1 (19.3)
Post-bronchodilator FEV1, L
a 1.45 (0.46)





≥ 2 antibiotic courses in prior year, %c 22.6
≥ 2 systemic corticosteroid courses in prior year, %c 9.2
Pulmonary treatm
Tiotropium, % 27.2
LABAs, total/monotherapy, % 48.1 / 8.5
ICS, total/monotherapy, % 49.5 / 9.9
LABA + ICS, % 39.6
Oral corticosteroids, % 2.0
Xanthines, % 20.2
Oxygen, % 0.6
aValues are means (SD) if not stated otherwise; b23 patients with GOLD category 1
The proportions of premature patient withdrawals were 16.9%, 18.3%, 13.0% and 1
respectively. Median exposure to study medication in all randomised and treated p
BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV1 = forc
Obstructive Lung Disease; ICS = inhaled corticosteroids; LABA = long-acting β2-agonsystemic corticosteroids or antibiotics due to breathing
problems in the preceding year (p < 0.0001) and were more
likely to be female (p < 0.0001) or ex-smokers (p < 0.0001).
Patients with severe exacerbations differed only slightly
in their baseline conditions from frequent exacerbators
except for severely impaired lung function and a higher
prevalence of male subjects (Table 1).
Similar patterns were observed in the sensitivity analyses
of patients who completed the protocol-defined treatment
period (Additional file 1: Table S2). Treatment of first
exacerbations was similar in infrequent and frequent
exacerbators (Table 2). Of 1330 subjects treated solely
with antibiotics for their first exacerbation, 35% suffered
from ≥ 1 subsequent exacerbation; while 1353 subjects
who had their first exacerbation treated with systemic cor-
ticosteroids or systemic corticosteroids plus antibiotics,
39.7% suffered from ≥ 1 subsequent exacerbation.
Exacerbation-related hospitalisations and mortality
The frequent exacerbator group (13.6% of the total study
population of 7376 patients) accounted for 56.6% (410/
725) of all hospitalisations due to exacerbations (severerequent exacerbators Frequent exacerbators Severe exacerbators
(n = 1687) (n = 1004) (n = 598)
72.1 70.9 82.1
63.0 (9.2) 63.0 (8.8) 64.2 (8.8)
26.4 (5.3) 26.4 (5.2) 25.8 (5.6)
8.2 (6.5) 8.8 (6.7) 9.1 (6.9)
50.3 41.7 44.6
38.2 (19.4) 39.4 (21.3) 40.3 (20.5)
1.36 (0.45) 1.32 (0.42) 1.22 (0.42)








55.1 / 7.6 61.6 / 7.1 54.8 / 5.4





COPD were included; cDue to breathing problems.
3.2% in the non-, infrequent, frequent and severe exacerbator subgroups,
atients was 361 days in severe exacerbators and 363 days in the other groups.
ed expiratory volume in 1 second; GOLD = Global Initiative for Chronic
ist; SD = standard deviation.
Table 2 Treatment of first exacerbations in the infrequent







(n = 1687) (n= 1004)
With antibioticsa 1481 (87.8) 827 (82.5)
With systemic corticosteroidsb 816 (48.5) 537 (53.3)
With antibiotics and
systemic corticosteroids
615 (36.5) 361 (36.0)
Hospitalisation 315 (18.7) 125 (12.5)
aRefers to n = 1686 for infrequent and n = 1003 for frequent exacerbators;
bRefers to n = 1684 for infrequent and n = 1004 for frequent exacerbators.
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crude exposure-adjusted rate of hospitalisations that was
twice as high for frequent exacerbators compared with
infrequent exacerbators (0.44 vs 0.21 hospitalised exacer-
bations per patient-year). The proportion of patients
with ≥ 1 severe exacerbation was 28.2% in the group of
frequent exacerbators and 18.7% in the group of infre-
quent exacerbators.
Patients with frequent exacerbations differed only slightly
from non- or infrequent exacerbators with regard to
all-cause mortality (vital status follow-up was complete
for 99.1% of all randomised and treated patients): the
incidence rates of fatal adverse events (AEs) (onset during
planned treatment and date of death up to Day 360)
were 1.74, 2.68 and 1.94 per 100 patient-years for
non-, infrequent and frequent exacerbators, respectively.
However, patients with severe exacerbations had an
exposure-adjusted incidence rate of fatal AEs that was
approximately three times higher than that of patients
without severe exacerbations (incidence rates 1.69, 5.40
and 5.37 per 100 patient-years for patients with 0, 1 or ≥ 2
severe exacerbations, respectively) (Figure 4).Figure 4 Incidence rates of all-cause mortality in patients with no exace
experiencing ≥ 1 severe exacerbation while on study treatment.Discussion
The present findings confirm, contrast, and extend previ-
ous investigations of exacerbation phenotypes in patients
with COPD. Firstly, it has been confirmed that the risk
for developing a frequent or severe exacerbation is largely
related to COPD severity, but also affects patients with
moderate disease. Secondly, it has been demonstrated
that frequent exacerbators accounted for the majority
of exacerbation-related hospitalisations, thus establishing
a link between frequency and severity of exacerbations.
Finally, it has been found that severe exacerbations
were associated with a distinct increase in mortality.
The baseline covariates associated with exacerbation
risk in our analysis included age, sex, GOLD category,
BMI, the use of concomitant ICS at baseline, COPD
duration, smoking history (pack-years) and the number of
previous courses of antibiotics or systemic corticosteroids,
thus reflecting similar findings from previous trials using
exacerbations as secondary endpoints [15-17].
To characterise ‘high-risk’ patients with frequent COPD
exacerbations, we categorised patients into non-, infre-
quent and frequent exacerbator subgroups. The patients
with frequent exacerbations tended to have more severe
disease, more pulmonary medication at baseline, and
treatment with ≥ 2 antibiotic or ≥ 2 systemic cortico-
steroid courses in the previous year. Severe exacerbations
particularly affected male patients and those with severely
impaired airflow limitation.
It is important to note that frequent or severe exacerba-
tions were not restricted to patients with severe airflow
limitation (GOLD category 3/4), but also occurred in a
significant proportion of patients with moderate COPD
(GOLD category 2), despite permitted co-medication and
active study treatment [18,19]. The clinical implications of
these findings are important, not least because patientsrbations, patients ≥ 1 moderate exacerbation, and patients
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the COPD patient population [20].
Compared with the Evaluation of COPD Longitudinally
to Identify Predictive Surrogate Endpoints (ECLIPSE)
study, the proportion of patients categorised as fre-
quent exacerbators was considerably lower in our pa-
tient population during the first year. Several reasons
may account for these differences, including a higher
proportion of patients with severe COPD in the ECLIPSE
study and, in particular, using different criteria for defining
exacerbations. In POET-COPD, pre-defined criteria
needed to be met for an event to be documented as a
moderate or severe exacerbation, while ECLIPSE had
no such criteria [8,12].
Another intriguing finding is the fact that a minority
of patients with frequent exacerbations accounted for
the majority of severe exacerbations. In addition, the
present analysis builds on previous reports linking severe
exacerbations to mortality [4,21,22]. Accordingly, we found
an incidence of mortality that was about three times higher
in patients with severe exacerbations, regardless of event
frequency. This observation, from a large prospective ex-
acerbation trial, supports recent GOLD recommendations
that even a single severe exacerbation indicates a high risk
of disease progression and poor outcome [3]. We could
not confirm recent observations by Lange et al. reporting
poorer survival in frequent exacerbators [22]. However,
such investigations certainly require longer-term follow-up.
Some limitations to the present study must be noted,
including the post-hoc nature of the analysis. In addition,
POET-COPD was a pharmacological intervention trial
rather than an epidemiological study, and the two treat-
ment interventions differed with respect to the primary
outcome. However, by including active study treatment
in our multivariate model, this potential source of differ-
ence was accounted for. Furthermore, the categorisation
into frequent and infrequent exacerbators was based on
actual treatment time, without performing a systematic
follow-up of exacerbations after premature withdrawal.
The higher premature withdrawal rate in non- and
infrequent exacerbators may have prevented some of
these subjects from being subsequently re-categorised
as frequent exacerbators. However, we assume that this
did not bias our conclusions given the comparable
median exposure ranges in the subgroups, as well as
the supportive results from the sensitivity analyses that
were restricted to patients who completed the protocol-
defined study treatment. Whether the exclusion of high-
risk patients may have altered the risk factors for the
frequency or severity of exacerbations requires further
study. It should be recognised, however, that some of
the exclusion criteria were required for consistency
with approved warnings and precautions associated
with the use of study medications. In POET-COPD, asin most other COPD trials, patients with a history of
asthma were excluded from trial participation. This
meant that patients with a COPD-asthma overlap,
which has been linked to the occurrence of more fre-
quent and severe respiratory exacerbations, were not
considered in our analysis [23]. However, it must be
noted that there is still much controversy about the desig-
nation of patients that share clinical characteristics of
COPD and asthma and final validation and clear diagnostic
criteria for this joint phenotype must be still developed
and prospectively validated [24]. It should also be
recognised that patients with characteristic cardiovascu-
lar conditions were represented in the study population.
Nevertheless, including high-risk patients, particularly
with cardiac illnesses, remains a challenging issue for
COPD trials [25].
Conclusions
Our analysis of a large COPD exacerbation trial shows
that patients with COPD with a frequent exacerbator
phenotype are more likely to be hospitalised. It remains
to be determined whether the frequent exacerbator
phenotype is a stable condition or varies over time de-
pending on the severity of exacerbations. There is also
the need to prospectively investigate the impact of co-
morbidities, e.g. cardiovascular, on the frequency and
severity of exacerbations of COPD. The fact that severe
exacerbations were associated with impaired survival
should prompt special awareness to the prevention of
any such events.
Additional file
Additional file 1: Table S1. Demographics and baseline characteristics
(completers only). Table S2. Multivariate model for time-to-first
exacerbation (all) and effect of covariates (completers only).
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